



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Docket No.: 010692-004532US

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

On JANUARY 9, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: Kimberly Rosa
Kimberly Rosa

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gorfine, Stephen R.

Application No.: 10/669,099

Filed: September 22, 2003

For: NITRIC OXIDE DONOR
COMPOSITION AND METHOD FOR
TREATMENT OF ANAL DISORDERS

Examiner: To be assigned

Art Unit: 1614

COMMUNICATION RE
SUPPLEMENTAL APPLICATION DATA
SHEET CORRECTING PRIORITY
CLAIM

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

According to MPEP 601.05, enclosed is a Supplemental Application Data Sheet Correcting Priority Claim . Applicant requests correction of the section entitled "Domestic Priority Information". Please note the correction on the marked up copy of

Gorfine, Stephen R.
Application No.: 10/699,099
Page 2

PATENT

page 2 of the initial Application Data Sheet, also attached to this Communication.

Respectfully submitted,



Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
FJM:kar

60114279 v1



UNITED STATES PATENT AND TRADEMARK OFFICE

010692-004532US FJM

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/669,099	09/22/2003	1614	0.00	010692-004532US		29	2

CONFIRMATION NO. 1846

20350

TOWNSEND AND TOWNSEND AND CREW, LLP
 TWO EMBARCADERO CENTER
 EIGHTH FLOOR
 SAN FRANCISCO, CA 94111-3834



FILING RECEIPT



OC000000011501443

Date Mailed: 12/17/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Stephen R. Gorfine, New York, NY;

Assignment For Published Patent Application

Cellegy Pharmaceuticals, Inc., South San Francisco, CA;

Domestic Priority data as claimed by applicant

This application is a CON of 10/021,168 12/11/2001 X
 which is a CON of 08/970,447 11/14/1997 ABN
 which is a CON of 08/666,264 06/20/1996 PAT 5,693,676
 which is a CON of 08/371,088 01/10/1995 ABN
 which is a CIP of 08/250,555 05/27/1994 PAT 5,504,117

~~X Data provided by applicant is not consistent with PTO records.~~

Foreign Applications

If Required, Foreign Filing License Granted: 12/15/2003

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Nitric oxide donor composition and method for treatment of anal disorders

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).